BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company's products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mechanical properties of tissues and materials. In addition, it manufactures ultra pure chitosans under the Ultrasan name; and offers manufacturing and analytical services. The company was incorporated in 1994 and is based in Laval, Canada. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. Biosyntech Inc. is in reorganization.